Emergent BioSolutions (EBS) Change in Accured Expenses (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Change in Accured Expenses of -$20.2 million for Q1 2026, up 37.27% year-over-year from -$14.7 million in Q1 2025, and down 220.24% quarter-over-quarter from $16.8 million in Q4 2025.
Emergent BioSolutions (EBS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$20.2 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 37.27% year-over-year to -$20.2 million; the TTM figure through Mar 2026 stood at $1.8 million (up 108.57% YoY), while the FY2025 annual figure was -$10.2 million, down 182.93% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$20.2 million, down from $16.8 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $22.2 million in Q4 2024, with the low at -$51.0 million in Q1 2022.
- The 5-year median for Change in Accured Expenses is -$8.1 million (2024), against an average of -$8.3 million.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses soared 187.06% in 2024, then tumbled 3027.27% in 2025.
- Emergent BioSolutions' Change in Accured Expenses stood at -$18.3 million in 2022, then slumped by 39.34% to -$25.5 million in 2023, then jumped by 187.06% to $22.2 million in 2024, then dropped by 24.32% to $16.8 million in 2025, then plunged by 220.24% to -$20.2 million in 2026.
- Business Quant data shows EBS's Change in Accured Expenses at -$20.2 million in Q1 2026, $16.8 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Mn |
| Jun 30, 2026 | 4.20 Mn |
| Mar 31, 2026 | -20.20 Mn |
| Mar 31, 2026 | -20.20 Mn |
| Dec 31, 2025 | 16.80 Mn |
| Dec 31, 2025 | 16.80 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | -32.20 Mn |
| Mar 31, 2025 | -32.20 Mn |
| Dec 31, 2024 | 22.20 Mn |
| Dec 31, 2024 | 22.20 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -8.10 Mn |
| Jun 30, 2024 | -8.10 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |